{"title":"Single-chain variable fragment antibodies targeting the antileukemia agent harringtonine for enzyme-linked immunosorbent assay development.","authors":"Seiichi Sakamoto, Shohei Komatsu, Ai Moriyasu, Gorawit Yusakul, Waraporn Putalun, Poomraphie Nuntawong, Hiroyuki Tanaka, Satoshi Morimoto","doi":"10.1080/15321819.2025.2526208","DOIUrl":null,"url":null,"abstract":"<p><p>In this study, we generated a single-chain variable fragment (scFv) specific to a potent antileukemic substance, harringtonine (HT) (HT-scFv) that can be used in enzyme-linked immunosorbent assay (ELISA) for the quantitative analysis of HT in the plant genus <i>Cephalotaxus</i>. The variable heavy (VH) and light chain (VL) genes were directly cloned from the cDNA of the hybridoma cell line 1D2, which secretes monoclonal antibody against HT (MAb 1D2). These genes were then assembled with a flexible peptide linker, specifically (Gly<sub>4</sub>Ser)<sub>3</sub>, through splicing by overlap extension PCR. The resulting HT-scFv gene was expressed in <i>Escherichia coli</i>. The denatured HT-scFv, produced as inclusion bodies, was solubilized and refolded using a dilution method to restore its functionality as an antibody. Characterization of the HT-scFv demonstrated its high specificity for HT. Additionally, its remarkable properties facilitated the development of an ELISA for HT detection, achieving a limit of detection (LOD) of 12.2 ng/mL. Furthermore, validation analyses showed that the ELISA using HT-scFv exhibited good accuracy and reliability for the quantitative assessment of HT in <i>C. harringtonia</i> \"Fastigiata.\" This study highlights the potential of HT-scFv as a valuable tool for ELISA in the quantitative analysis of HT.</p>","PeriodicalId":15990,"journal":{"name":"Journal of immunoassay & immunochemistry","volume":" ","pages":"519-534"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of immunoassay & immunochemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/15321819.2025.2526208","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Health Professions","Score":null,"Total":0}
引用次数: 0
Abstract
In this study, we generated a single-chain variable fragment (scFv) specific to a potent antileukemic substance, harringtonine (HT) (HT-scFv) that can be used in enzyme-linked immunosorbent assay (ELISA) for the quantitative analysis of HT in the plant genus Cephalotaxus. The variable heavy (VH) and light chain (VL) genes were directly cloned from the cDNA of the hybridoma cell line 1D2, which secretes monoclonal antibody against HT (MAb 1D2). These genes were then assembled with a flexible peptide linker, specifically (Gly4Ser)3, through splicing by overlap extension PCR. The resulting HT-scFv gene was expressed in Escherichia coli. The denatured HT-scFv, produced as inclusion bodies, was solubilized and refolded using a dilution method to restore its functionality as an antibody. Characterization of the HT-scFv demonstrated its high specificity for HT. Additionally, its remarkable properties facilitated the development of an ELISA for HT detection, achieving a limit of detection (LOD) of 12.2 ng/mL. Furthermore, validation analyses showed that the ELISA using HT-scFv exhibited good accuracy and reliability for the quantitative assessment of HT in C. harringtonia "Fastigiata." This study highlights the potential of HT-scFv as a valuable tool for ELISA in the quantitative analysis of HT.
期刊介绍:
The Journal of Immunoassay & Immunochemistry is an international forum for rapid dissemination of research results and methodologies dealing with all aspects of immunoassay and immunochemistry, as well as selected aspects of immunology. They include receptor assay, enzyme-linked immunosorbent assay (ELISA) in all of its embodiments, ligand-based assays, biological markers of ligand-receptor interaction, in vivo and in vitro diagnostic reagents and techniques, diagnosis of AIDS, point-of-care testing, clinical immunology, antibody isolation and purification, and others.